Introduction: Approximately one third of diffuse large B-cell lymphomas (DLBCL) arises from tissues different from the lymph node. Perceived differences in outcome between extranodal and nodal DLBCL raise the possibility that these subgroups may represent different biological and clinical entities. Methods: Microarray GeneChip technology was used for global gene expression profiles from nodal (n = 19) and extranodal (n = 8) DLBCL, to examine possible differences between these subgroups. Quantitative RT-PCR was employed for validation of microarray data. Differential expression levels of p16 (CDKN2A) were confirmed by means of immunohistochemistry on a tissue microarray comprising more than 200 lymphoma samples. Results: A total of 218, over (124)- and underexpressed (94) genes were found to be differentially expressed in extranodal DLBCL compared with nodal DLBCL, including cytokines/chemokines, chromosome-replication-related genes and DNA repair genes. Quantitative RT-PCR confirmed the microarray data. A higher rate of p16 positivity was found in extranodal lymphomas. However, prognostic importance of p16 was associated with nodal rather than extranodal lymphomas. Conclusion: Our data suggest that a better distinction of these subgroups based on molecular classifiers is feasible and may greatly facilitate the determination of specific relevant clinical features and therapeutic implications of DLBCL with primary extranodal or nodal location.

Keywords:
Diffuse large B-cell lymphoma, Extranodal lymphomas, Gene expression, Nodal lymphomas
1.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.
2.
Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998;9:717–720.
3.
Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and genetics of tumours of the hematopoietic and lymphoid tissues. WHO Classification of Tumours. Lyon, IARC Press, 2001.
4.
Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP: Report of the first workshop on prognostic factors in large-cell lymphomas. Ann Oncol 1991;2(suppl 2):213–217.
5.
Shipp MA: Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has ‘high-risk’ disease? Blood 1994;83:1165–1173.
6.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
7.
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 2002;8:68–74.
8.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
9.
Otter R, Gerrits WB, vd Sandt MM, Herman J, Willmzer R: Primary extranodal and nodal non-Hodgkin’s lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol 1989;25:1203–1210.
10.
d’Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, Pedersen M, Jensen MK, Johansen P, Andersen E, et al: Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphoma. Danish LYFO Study Group. Eur J Cancer 1991;27:1201–1208.
11.
Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM: Clinical relevance of BCL2, BCL6 and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.
12.
López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E: Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797–2804.
13.
Beà S, Colomo L, López-Guillermo A, Salaverria I, Puig X, Pinyol M, Rives S, Montserrat E, Campo E: Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphoma. J Clin Oncol 2004;22:3498–3506.
14.
Zucca E, Roggero E, Bertoni F, Cavalli F: Primary extranodal non-Hodgkin’s lymphomas. Part 1. Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727–737.
15.
Groves FD, Linet MS, Travis LB, Devesa SS: Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240–1251.
16.
Huber W, Gentleman R: Matchprobes: a Bioconductor package for the sequence-matching of microarray probe elements. Bioinformatics 2004;20:1651–1652.
17.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
18.
Seo J, Hoffman EP: Probe set algorithms: is there a rational best bet? BMC Bioinformatics 2006;7:395.
19.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249–264.
20.
Benjamini Y, Hochberg Y: The adaptive control of the false discovery rate in multiple hypotheses testing. J Behav Educ Statist 2000;25:60–83.
21.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:Research0034.
22.
Gutiérrez MI, Timson G, Siraj AK, Bu R, Barbhaya S, Banavali S, Bhatia K: Single monochrome real-time RT-PCR assay for identification, quantification and breakpoint cluster region determination of t(9;22) transcripts. J Mol Diagn 2005;7:40–47.
23.
Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
24.
Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 1998;4:844–847.
25.
Al-Kuraya KS, Siraj AK, Al-Dayel FA, Ezzat AA, Al-Jommah NA, Atizado VL, Narayappa RN: Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases. Saudi Med J 2005;26:1099–1103.
26.
Sáez AI, Sáez AJ, Artiga MJ, Pérez-Rosado A, Camacho FI, Díez A, García JF, Fraga M, Bosch R, Rodríguez-Pinilla SM, Mollejo M, Romero C, Sánchez-Verde L, Pollán M, Piris MA: Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613–622.
27.
Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, Lee SS, Kim WH, Kim CW: Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. Histopathology 2005;47:281–291.
28.
Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001;67:61–70.
29.
Moller MB, Pedersen NT, Christensen BE: Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation – a population-based study of 1,575 cases. Br J Haematol 2004;124:151–159.
30.
Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P: Somatic Fas mutations in non-Hodgkin’s lymphomas: association with extranodal disease and autoimmunity. Blood 1998;92:3018–3024.
31.
Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RS: REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25–29.
32.
Goodlad JR, MacPherson S, Jackson R, Batstone P, White J: Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal site. Histopathology 2004;44:268–276.
33.
Offit K, Coco FL, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanvar S, Favera RD, Chaganti RSK: Rearrangement of the bcl6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994;331:74–80.
34.
Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH: Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol 2005;29:69–82.
35.
Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Aït-Yahia S, Brière F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373–386.
36.
Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, Lipp M: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23–33.
37.
Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.
38.
López-Giral S, Quintana NE, Cabrerizo M, Alfonso-Pérez M, Sala-Valdés M, De Soria VG, Fernández-Rañada JM, Fernández-Ruiz E, Muñoz C: Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004;76:462–471.
39.
Ohl L, Henning G, Krautwald S, Lipp M, Hardtke S, Bernhardt G, Pabst O, Förster R: Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J Exp Med 2003;197:1199–1204.
40.
Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, Cyster JG: Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002;416:94–99.
41.
Ngo VN, Tang HL, Cyster JG: Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells: J Exp Med 1998;188:181–191.
42.
Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG: Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci USA 2000;97:12694–12699.
43.
Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004;35:233–245.
44.
Shen Y, Iqbal J, Xiao L, Lynch RC, Rosenwald A, Staudt LM, Sherman S, Dybkaer K, Zhou G, Eudy JD, Delabie J, McKeithan TW, Chan WC: Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. BMC Immunol 2004;5:20.
45.
Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, David D, Chaplin D: Signaling through TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13/CCL19/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells into the B cell follicle. J Immunol 2001;167:1920–1928.
46.
Bendriss-Vermare N, Chaperot L, Peoc’h M, Vanbervliet B, Jacob MC, Briere F, Bensa JC, Caux C, Plumas J: In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia 2004;18:1491–1498.
47.
Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M: Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005;106:1770–1777.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.